ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) Sellers Decreased Their Shorts By 91.01%

May 16, 2018 - By Michele Cranor

Argos Therapeutics, Inc. (OTCMKTS:ARGS) Corporate Logo

During Q4 2017 the big money sentiment increased to 0.85. That’s change of 0.22, from 2017Q3’s 0.63. 8 investors sold all, 5 reduced holdings as Argos Therapeutics, Inc. ratio increased. 5 grew stakes while 6 funds acquired stakes. Funds hold 2.48 million shares thus 6.25% less from 2017Q3’s 2.64 million shares.
Virtu Finance Ltd Liability Co has invested 0% of its capital in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Guggenheim Ltd Liability Com has 24,877 shs. Wasatch Advisors Inc reported 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Deutsche Natl Bank Ag stated it has 36 shs or 0% of all its holdings. Northern Tru Corp reported 43,244 shs. Two Sigma Secs Limited Liability Corp owns 47,961 shs. Keybank Association Oh reported 119,515 shs. Stifel Corp invested 0% of its capital in Argos Therapeutics, Inc. (OTCMKTS:ARGS). California Employees Retirement Sys has 94,800 shs. Royal Bancorp Of Canada has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Natl Bank Of Ny Mellon, a New York-based fund reported 24,052 shs. State Street invested in 0% or 11,900 shs. Credit Suisse Ag accumulated 20,074 shs. Vanguard Group Inc Inc accumulated 1.05M shs. Meeder Asset Mgmt Inc reported 0% stake.

ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) registered a decrease of 91.01% in shorted shares. In May was announced ARGS’s total 65,500 shorted shares by FINRA. The down change of 91.01% from 728,400 shares was reported.

Ticker’s shares touched $0.172 during the last trading session after 9.43% change.Currently Argos Therapeutics, Inc. is downtrending after 87.69% change in last May 16, 2017. ARGS has also 67,166 shares volume. ARGS underperformed the S&P 500 by 99.24%.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America.The company has $1.82 million market cap. The firm develops immunotherapies based on its proprietary technology platform, Arcelis.Last it reported negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.